Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03108131 · OUTCOME

Progression-Free Survival (PFS)

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors · Source last updated 2025-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
3 years

What was measured

Progression free survival (PFS) is defined as the time from randomization until first evidence of disease progression or death

Groups in this outcome

Small Bowel Adenocarcinoma

Must be refractory or intolerant to at least one line of 5FU-based chemotherapy for metastatic disease and must not have clinically symptomatic malignant small bowel obstruction. Cobimetinib (60 mgorally once daily for days 1 - 21) and atezolizumab (840 mg intravenously every 2 weeks) every 28-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Small Bowel Adenocarcinoma20

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Small Bowel Adenocarcinoma2.4Not reported1.33.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.3
        upper Limit
        3.5
        value
        2.4
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
Progression free survival (PFS) is defined as the time from randomization until first evidence of disease progression or death
dispersion Type
95% Confidence Interval
groups
  1. description
    Must be refractory or intolerant to at least one line of 5FU-based chemotherapy for metastatic disease and must not have clinically symptomatic malignant small bowel obstruction. Cobimetinib (60 mgorally once daily for days 1 - 21) and atezolizumab (840 mg intravenously every 2 weeks) every 28-day cycle.
    id
    OG000
    title
    Small Bowel Adenocarcinoma
param Type
MEDIAN
reporting Status
POSTED
time Frame
3 years
title
Progression-Free Survival (PFS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice